Merck's Strong Q4 Tempered by Cautious 2026 Outlook as Keytruda Patent Cliff Looms
While Merck (MSD) delivered robust fourth-quarter results, its forecast for 2026 fell below Wall Street expectations, highlighting investor anxiety over impending patent expiries for blockbuster drugs like Keytruda.